Open AccessALTERATION OF THE DISMAL NATURAL HISTORY OF FIBROSING CHOLESTATIC HEPATITIS SECONDARY TO HEPATITIS B VIRUS WITH THE USE OF LAMIVUDINE
Author(s) -
Khalid Al Faraidy,
Eric M. Yoshida,
Jennifer Davis,
Robert K. Vartanian,
Frank H. Anderson,
Urs P. Steinbrecher
Publication year - 1997
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/00007890-199709270-00024
Subject(s) - lamivudine , medicine , immunosuppression , gastroenterology , hepatitis b virus , ganciclovir , liver transplantation , natural history , hepatitis b , jaundice , hbeag , immunology , transplantation , hepatitis , virus , hbsag , human cytomegalovirus
Fibrosing cholestatic hepatitis (FCH) is a severe form of hepatitis B virus (HBV) infection occurring as either primary allograft reinfection after liver transplantation for HBV or as severe HBV reactivation induced by immunosuppression in patients with previously latent infection. Without treatment, FCH is universally fatal within a few months of diagnosis. Some improvement has been reported with long-term ganciclovir, with and without foscarnet, but an effective and easily available treatment has not yet been reported.